Is Celldex Therapeutics, Inc. (CLDX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 26.5% / 30% | 0.1% / 30% | 1851.78% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 26.5% / 33% | 0.1% / 33% | 1851.78% / 5% | ✗ NOT HALAL |
| MSCI | 0.4% / 33% | 89.0% / 33% | 0.3% / 33% | 1851.78% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 26.5% / 33% | 0.1% / 33% | 1851.78% / 5% | ✗ NOT HALAL |
| FTSE | 0.4% / 33% | 89.0% / 33% | 0.3% / 50% | 1851.78% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -72027.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -40.6% | |
| Return on Assets (ROA) | -26.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$211M |
| Free Cash Flow | -$214M |
| Total Debt | $2M |
| Debt-to-Equity | 0.4 |
| Current Ratio | 10.5 |
| Total Assets | $583M |
Price & Trading
| Last Close | $31.75 |
| 50-Day MA | $27.25 |
| 200-Day MA | $25.20 |
| Avg Volume | 847K |
| Beta | 1.3 |
|
52-Week Range
$14.40
| |
About Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Celldex Therapeutics, Inc. (CLDX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Celldex Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Celldex Therapeutics, Inc.'s debt ratio?
Celldex Therapeutics, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.4%.
What are Celldex Therapeutics, Inc.'s key financial metrics?
Celldex Therapeutics, Inc. has a market capitalization of $2.0B, and revenue of $2M. Return on equity stands at -40.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.